

# Reference Data

Fiscal Year 2020  
(April 1, 2020 to March 31, 2021)

## Consolidated Earnings

- Consolidated Financial Data p. 1
- Consolidated Balance Sheets p. 2
- Consolidated P/L Statement p. 3
- Consolidated Sales Breakdown by Segment/Category p. 4
- Consolidated Operating Profit by Segment p. 4
- Consolidated Sales -
  - Leading Brands of Self-Medication Operations
  - Sales by Region p. 5
- Consolidated Sales -
  - Leading Products of Prescription Pharmaceutical Operations p. 6
- Capital Expenditure p. 7
- Depreciation and Amortization p. 7
- R&D Expenses p. 7
- Results of Major Consolidated Subsidiary
  - ♦ Taisho Pharmaceutical p. 8
- Major Subsidiaries and Affiliates p. 9
- Shareholders Information p. 10
- Prescription Pharmaceutical Operations:
  - New Drug Development-Taisho Pharmaceutical p. 11
- Status of New Products p. 13

Taisho Pharmaceutical Holdings Co.,Ltd.

## Consolidated Financial Data

(Millions of yen)

	March 2018**** (FY2017)	March 2019 (FY2018)	March 2020*** (FY2019)	March 2021 (FY2020)	(Est) March 2022 Before deduction of sales	(Est) March 2022***** After deduction of sales
Net sales	280,092	261,551	288,527	281,980	284,000	269,000
(YOY%)	(+0.1%)	(-6.6%)	(+10.3%)	(-2.3%)	(+0.7%)	(-4.6%)
Self-Medication operations	183,996	180,123	220,027	226,878	242,900	231,100
Prescription Pharmaceutical operations	96,096	81,428	68,500	55,101	41,100	37,900
Gross profit on sales*	182,984	170,163	180,333	175,986	179,200	165,500
Selling, general and administrative expenses	146,007	138,951	159,196	156,021	164,700	151,000
Research and development expenses (% Sales)	21,150 (7.6%)	20,801 (8.0%)	22,876 (7.9%)	20,251 (7.2%)	21,600 (7.6%)	21,600 (8.0%)
Advertising expenses	22,579	20,206	26,046	25,017	32,000	32,000
Sales promotion expenses	28,636	27,125	27,440	24,527	23,300	13,100
Personnel expenses	35,241	32,491	31,017	32,953	33,100	33,100
Operating Profit	36,977	31,211	21,137	19,965	14,500	14,500
(YOY%)	(+15.7%)	(-15.6%)	(-32.3%)	(-5.5%)	(-27.4%)	(-27.4%)
Earnings before the amortization of goodwill and trademarks	40,965	35,201	29,470	32,008	26,400	26,400
Ordinary Profit	42,140	40,851	24,474	25,946	18,500	18,500
(YOY%)	(+10.8%)	(-3.1%)	(-40.1%)	(+6.0%)	(-28.7%)	(-28.7%)
Profit attributable to owners of parent	31,679	48,593	20,172	13,316	10,500	10,500
(YOY%)	(+10.1%)	(+53.4%)	(-58.5%)	(-34.0%)	(-21.1%)	(-21.1%)
Comprehensive income	36,627	48,027	8,470	28,920	-	-
(YOY%)	(+21.3%)	(+31.1%)	(-82.4%)	(+241.4%)	-	-
Basic EPS (yen)	396.54	608.80	252.74	166.84	131.45	131.45
Diluted EPS (yen)	396.20	608.22	252.44	166.63	131.29	131.29
BPS (yen)	8,452.12	8,924.23	8,887.84	9,129.95	9,158.01	9,158.01
Dividend per share (yen)	110.00	120.00	110.00	100.00	100.00	100.00
Payout ratio	27.7%	19.7%	43.5%	59.9%	76.1%	76.1%
Capital expenditure	4,857	5,259	9,469	15,121	17,600	17,600
Depreciation and amortization	10,154	10,073	12,610	14,700	14,000	14,000
Total assets****	799,616	821,782	864,974	876,923	879,000	879,000
Shareholders' equity	691,318	724,137	739,778	758,406	761,000	761,000
Return on equity (%)**	4.8%	7.0%	2.8%	1.9%	1.4%	1.4%
Return on assets (%)**	4.0%	6.0%	2.4%	1.5%	1.2%	1.2%
Equity ratio (%)****	84.4%	86.7%	82.0%	83.1%	83.2%	83.2%
Overseas sales	30,936	30,978	69,500	92,607	98,400	98,400
Overseas sales ratio (% of total sales)	11.0%	11.8%	24.1%	32.8%	36.6%	36.6%
Number of employees	6,340	5,142	9,354	9,195	-	-

\* After provision/reversal of reserve for returned unsold goods

\*\* Average of the beginning and year-end balance of shareholders' equity / total assets

\*\*\* Figures for the previous fiscal year have been revised retrospectively to reflect determination of allocation of acquisition-related costs in business combinations.

\*\*\*\* Total assets and equity ratio for FY2017 have been revised retrospectively to reflect partial revision of the tax effect accounting standards.

\*\*\*\*\* The accounting standard for revenue recognition will apply from FY2021 onwards.

# Consolidated Balance Sheets

(Millions of yen)

(millions of yen)

	End of FY2019		End of FY2020		change	
	(March 31, 20)	% total	(March 31, 21)	% total		
(Assets)						
I Current assets:	355,623	41.1%	357,731	40.8%	+2,108	
Cash and deposits	223,814		250,178		+26,363	
Notes and accounts receivable-trade	65,463		51,609		-13,854	
Marketable securities	14,089		4,017		-10,071	
Inventories	43,371		46,384		+3,013	
Other	8,884		5,540		-3,343	
II Fixed assets:	509,351	58.9%	519,192	59.2%	+9,840	
(1) Tangible fixed assets:	112,648	(13.0%)	113,194	(12.9%)	+545	
Buildings and structures	53,999		51,876		-2,122	
Machinery, equipment and vehicles	15,059		14,494		-565	
Land	38,170		37,429		-741	
Other	5,418		9,393		+3,974	
(2) Intangible fixed assets:	221,811	(25.6%)	216,532	(24.7%)	-5,278	
Goodwill	133,169		128,612		-4,557	
Sales rights	690		453		-236	
Trademarks	73,144		69,258		-3,886	
Software	6,570		10,341		+3,771	
Other	8,236		7,867		-369	
(3) Investments and other assets:	174,891	(20.2%)	189,464	(21.6%)	+14,572	
Investment securities	145,831		156,055		+10,223	Affected by an increase in the share price
Shares of subsidiaries and affiliates	11,644		12,261		+617	
Net defined benefit assets	4,642		10,620		+5,977	
Deferred tax assets	11,134		8,892		-2,242	
Other	1,638		1,634		-3	
Total assets	864,974	100.0%	876,923	100.0%	+11,948	
(Liabilities)						
I Current liabilities:	66,456	7.7%	57,666	6.6%	-8,789	
Notes and accounts payable-trade	18,045		14,672		-3,373	
Accounts payable	15,743		16,068		+325	
Accrued income taxes	5,414		3,275		-2,138	
Provision for bonuses	3,769		3,523		-246	
Other	23,482		20,126		-3,356	
II Long-term liabilities:	58,739	6.8%	60,849	6.9%	+2,109	
Net defined benefit liabilities	21,029		21,321		+291	
Deferred taxes liabilities	30,042		32,747		+2,704	
Other	7,666		6,780		-886	
Total liabilities	125,196	14.5%	118,516	13.5%	-6,679	
(Net assets)						
I Shareholders' equity	692,768	80.1%	697,598	79.6%	+4,829	
Common stock	30,000		30,000		-	
Capital surplus	-		12		+12	
Retained earnings	698,223		703,036		+4,812	Profit attributable to owners of parent+13,316
Treasury stock	-35,454		-35,450		+4	
II Accumulated other comprehensive income	16,605	1.9%	31,105	3.5%	+14,500	
Valuation difference on securities	20,796		30,026		+9,230	Affected by an increase in the share price
Foreign currency translation adjustment	-1,145		-235		+909	
Remeasurements of defined benefit plans	-3,046		1,315		+4,361	
III Share acquisition rights	773	0.1%	801	0.1%	+27	
IV Non-controlling interests	29,630	3.4%	28,900	3.3%	-729	
Total net assets	739,778	85.5%	758,406	86.5%	+18,628	
Total liabilities and net assets	864,974	100.0%	876,923	100.0%	+11,948	

\* Figures for the previous fiscal year have been revised retrospectively to reflect determination of allocation of acquisition-related costs in business combinations.

# Consolidated P/L Statement

(Millions of yen)

	End of FY2019		End of FY2020		YOY change	
	(March 31, 20)	% total	(March 31, 21)	% total		
Net sales	288,527	100.0%	281,980	100.0%	-6,547	
Cost of sales	108,386	37.6%	106,050	37.6%	-2,336	
Gross profit on sales	180,140	62.4%	175,929	62.4%	-4,211	
Provision for sales returns	-192		-57		+135	
Gross profit	180,333	62.5%	175,986	62.4%	-4,346	
Selling, general and administrative expenses	159,196	55.2%	156,021	55.3%	-3,174	
Research and development expenses	22,876		20,251		-2,624	
Advertising expenses	26,046		25,017		-1,029	
Sales promotion expenses	27,440		24,527		-2,912	
Personnel expenses	31,017		32,953		+1,936	
Other	51,815		53,271		+1,455	
Operating Profit	21,137	7.3%	19,965	7.1%	-1,172	
Non-operating income	6,619	2.3%	6,483	2.3%	-135	
Non-operating expenses	3,282	1.1%	502	0.2%	-2,779	FY2019: Foreign exchange losses 2,746
Ordinary Profit	24,474	8.5%	25,946	9.2%	+1,471	
Extraordinary income	6,133	2.1%	24	0.0%	-6,108	FY2019: Gains attributable to phased acquisition 6,093
Extraordinary losses	832	0.3%	2,994	1.1%	+2,161	FY2020: Impairment loss 2,250
Profit before income taxes and minority interests	29,775	10.3%	22,976	8.1%	-6,798	
Income taxes	8,245	2.9%	7,782	2.8%	-463	
Profit	21,529	7.5%	15,194	5.4%	-6,334	
Profit attributable to non-controlling interests	1,356	0.5%	1,878	0.7%	+521	
Profit attributable to owners of parent	20,172	7.0%	13,316	4.7%	-6,856	

\* Figures for the previous fiscal year have been revised retrospectively to reflect determination of allocation of acquisition-related costs in business combinations.

## Consolidated Sales Breakdown by Segment/Category

(Millions of yen)

	March 2018 (FY2017)	March 2019 (FY2018)	March 2020 (FY2019)	March 2021 (FY2020)	(Est) March 2022 Before deduction of sales	(Est) March 2022* Full-Year
Self-Medication operations	183,996	180,123	220,027	226,878	242,900	231,100
(YOY%)	(+2.2%)	(-2.1%)	(+22.2%)	(+3.1%)	(+7.1%)	(+1.9%)
Japan	150,191	145,983	147,062	130,892	141,600	131,300
Overseas	30,921	30,867	69,440	92,490	98,000	98,000
Other	2,884	3,272	3,523	3,495	3,300	1,800
Prescription Pharmaceutical operations	96,096	81,428	68,500	55,101	41,100	37,900
(YOY%)	(-3.7%)	(-15.3%)	(-15.9%)	(-19.6%)	(-25.4%)	(-31.2%)
Ethical drugs	91,259	79,460	67,022	54,203	40,000	36,800
Other	4,837	1,967	1,477	898	1,100	1,100
Total	280,092	261,551	288,527	281,980	284,000	269,000

\* The accounting standard for revenue recognition will apply from FY2021 onwards.

## Consolidated Operating Profit by Segment

(Millions of yen)

	March 2018 (FY2017)	March 2019 (FY2018)	March 2020** (FY2019)	March 2021 (FY2020)	March 2022*** (FY2021)
Self-Medication operations	30,162	30,287	18,694	19,395	20,500
(YOY%)	(+0.2%)	(+0.4%)	(-38.3%)	(+3.7%)	(+5.7%)
Earnings before the amortization of goodwill and trademarks	34,151	34,276	27,027	31,438	32,400
Prescription Pharmaceutical operations (YOY%)	8,207	2,685	4,144	2,495	-4,000
	(+144.8%)	(-67.3%)	(+54.4%)	(-39.8%)	(-)
Other*	-1,393	-1,760	-1,702	-1,925	-2,000
(YOY%)	(-)	(-)	(-)	(-)	(-)
Total	36,977	31,211	21,137	19,965	14,500

\* The "Other" segment represents the Company (a pure holding company), which is not attributable to any reportable segment.

\*\* Figures for the FY2019 have been revised retrospectively to reflect determination of allocation of acquisition-related costs in business combinations.

\*\*\*The accounting standard for revenue recognition will apply from FY2021 onwards.

## Consolidated Sales - Leading Brands of Self-Medication Operations & Sales by Region

(Billions of Yen)

	March 2018 (FY2017)	March 2019 (FY2018)	March 2020 (FY2019)	March 2021		(Est) March 2022*	
				(FY2020)	YOY	(FY2021)	YOY
Japan	150.2	146.0	147.1	130.9	-11.0%	131.3	+0.3%
<i>Lipovitan</i> series	54.7	52.0	50.9	45.8	-10.0%	49.0	+6.9%
<i>Pabron</i> series	28.9	28.9	29.8	21.1	-29.1%	22.0	+4.1%
<i>RiUP</i> series	16.5	15.3	14.9	14.9	-0.2%	15.3	+2.9%
<i>Biofermin</i> series	8.6	10.2	10.7	9.8	-8.8%	10.3	+5.9%
<i>NARON</i> series	3.2	3.0	3.1	3.0	-2.3%	3.5	+14.8%
GI treatment series	3.9	3.7	3.7	3.4	-9.2%	3.5	+3.0%
<i>VICKS</i> series	4.0	4.0	4.3	3.1	-28.3%	3.5	+11.4%
<i>Livita</i> series	3.5	3.4	3.4	3.2	-4.3%	3.2	+0.7%
<i>Colac</i> series	3.3	3.0	3.2	3.1	-1.9%	3.1	-1.9%
Overseas	30.9	30.9	69.4	92.5	+33.2%	98.0	+6.0%
Asia	27.2	27.6	42.5	41.6	-2.0%	46.1	+10.8%
Europe and America	2.2	1.9	25.8	49.7	+92.8%	50.9	+2.5%
Others	2.9	3.3	3.5	3.5	-0.8%	1.8	-48.5%

(Rounded to the nearest hundred-million)

\* The forecast by major brands reflects the figures before application of the accounting standard for revenue recognition.

### *Lipovitan* Series: Sales Breakdown

(Billions of Yen)

	March 2018 (FY2017)	March 2019 (FY2018)	March 2020 (FY2019)	March 2021		(Est) March 2022*	
				(FY2020)	YOY	(FY2021)	YOY
<i>Lipovitan</i> series	54.7	52.0	50.9	45.8	-10.0%	49.0	+6.9%
<i>Lipovitan D</i>	35.3	33.4	32.1	28.7	-10.8%	29.9	+4.1%
Others	19.5	18.7	18.7	17.1	-8.7%	19.1	+11.6%

(Rounded to the nearest hundred-million)

\* The forecast by major brands reflects the figures before application of the accounting standard for revenue recognition.

## Consolidated Sales - Leading Products of Prescription Pharmaceutical Operations

(Billions of Yen)

	March 2018 (FY2017)	March 2019 (FY2018)	March 2020 (FY2019)	March 2021		(Est) March 2022*	
				(FY2020)	YOY	(FY2021)	YOY
<i>Edirol</i>	25.4	26.2	27.0	16.2	-39.9%	-	-
<i>Lusefi</i>	5.0	5.6	7.1	10.8	+51.5%	14.0	+29.6%
<i>Bonviva</i>	6.5	6.4	6.6	6.9	+4.7%	7.1	+3.1%
<i>LOQOA</i>	3.1	3.5	3.9	3.8	-2.3%	4.5	+18.2%
<i>Biofermin</i>	4.0	3.9	3.8	3.4	-10.6%	4.5	+32.4%
<i>Clarith</i>	7.7	5.3	4.3	2.2	-48.7%	1.9	-13.1%
<i>Palux</i>	4.9	3.5	3.1	2.4	-24.2%	1.9	-20.2%
<i>Geninax</i>	4.4	3.5	3.9	2.2	-43.9%	1.0	-54.6%

(Rounded to the nearest hundred-million)

\* The forecast by major product reflects the figures before application of the accounting standard for revenue recognition.

## Consolidated: Capital Expenditure

(Millions of yen)

	March 2018 (FY2017)	March 2019 (FY2018)	March 2020 (FY2019)	March 2021 (FY2020)	(Est) March 2022 (FY2021)
Total capital expenditure	4,857	5,259	9,469	15,121	17,600
Taisho Pharmaceutical	4,054	3,974	6,471	7,793	10,350
Production department	1,331	1,061	1,597	1,379	1,210
Research department	1,084	979	940	1,519	5,540
Head Office and the others	1,638	1,932	3,933	4,894	3,600
Other subsidiaries	803	1,285	2,998	7,327	7,250

## Consolidated: Depreciation and Amortization

(Millions of yen)

	March 2018 (FY2017)	March 2019 (FY2018)	March 2020* (FY2019)	March 2021 (FY2020)	(Est) March 2022 (FY2021)
Depreciation and amortization	10,154	10,073	12,610	14,700	14,000
Cost of sales	3,085	3,225	4,325	5,278	4,700
SGA expenses	7,068	6,847	8,284	9,421	9,300

\* Figures for the FY2019 have been revised retrospectively to reflect determination of allocation of acquisition-related costs in business combinations.

## Consolidated: R&D Expenses

(Millions of yen)

	March 2018 (FY2017)	March 2019 (FY2018)	March 2020 (FY2019)	March 2021 (FY2020)	(Est) March 2022 (FY2021)
Total R&D expenses	21,150	20,801	22,876	20,251	21,600
Self-Medication operations	5,983	5,353	6,754	7,492	7,900
Prescription Pharmaceutical operations	15,167	15,447	16,121	12,758	13,700

## Results of Major Consolidated Subsidiaries

### Sales and earnings of Taisho Pharmaceutical

(Billions of Yen)

	March 2018 (FY2017)	March 2019 (FY2018)	March 2020 (FY2019)	March 2021	
				(FY2020)	YOY
Net Sales	205.2	192.9	217.5	190.2	-12.6%
Self-Medication	151.9	147.7	149.2	135.2	-9.4%
Prescription Pharmaceutical	53.2	45.2	68.3	55.0	-19.5%
Operating profit	25.9	20.3	19.9	16.5	-17.1%
Ordinary profit	33.6	27.9	20.9	27.8	+33.1%
Profit	28.2	11.5	14.9	18.5	+23.9%

(Rounded to the nearest hundred-million)

## Major Subsidiaries and Affiliates

(As of March 31, 2021)

Company	Address	Capital	Business	Ownership*
(1) Consolidated subsidiaries				%
Taisho Pharmaceutical Co., Ltd.	Tokyo, Japan	,000 Yen 29,837,892	SMG PD	100.0
MEJIRO KOSAN Co., Ltd.	Tokyo, Japan	,000 Yen 600,000	SMG	100.0
Taisho Okinawa Co., Ltd.	Okinawa, Japan	,000 Yen 50,000	SMG	100.0
Taisho M.T.C. Co., Ltd.	Tokyo, Japan	,000 Yen 400,000	SMG	60.0
Taisho Pharmaceutical Logistics Co., Ltd.	Saitama, Japan	,000 Yen 30,000	SMG	100.0
Biofermin Pharmaceutical Co., Ltd.	Hyogo, Japan	,000 Yen 1,227,000	SMG PD	63.9
Taisho Pharma Co., Ltd.	Tokyo, Japan	,000 Yen 100,000	PD	100.0
TAISHO ACTIVE HEALTH Co., Ltd.	Tokyo, Japan	,000 Yen 100,000	SMG	55.0
TOKUHON Corporation	Tokyo, Japan	,000 Yen 300,000	SMG PD	100.0
Dr. Program Co., Ltd.	Tokyo, Japan	,000 Yen 251,500	SMG	100.0
Taisho Pharmaceutical (Taiwan) Co., Ltd.	Taiwan	,000 NT\$ 200,000	SMG	100.0
Taisho Pharmaceutical California Inc.	U.S.A.	,000 US\$ 41,050	SMG	100.0
Taisho Pharmaceuticals (Philippines), Inc.	Philippines	,000 Peso 18,900	SMG	100.0
Taisho Co., Ltd. Shanghai	China	,000 CNY 132,621	SMG	100.0
Taisho Vietnam Co., Ltd.	Vietnam	,000 VND 170,754,300	SMG	100.0
Taisho Pharmaceutical (H.K.) Ltd.	China	,000 HK\$ 10,000	SMG	100.0
Osotspha Taisho Pharmaceutical Co., Ltd.	Thailand	,000 THB 100,000	SMG	60.0
Taisho Pharmaceutical R&D Inc.	U.S.A.	,000 US\$ 4,000	PD	100.0
PT. Taisho Pharmaceutical Indonesia Tbk	Indonesia	,000 rupiah 10,240,000	SMG	98.6
Taisho Pharmaceutical Singapore Private Limited	Singapore	,000 US\$ 1,365	SMG	100.0
Hoepharm Holdings Sdn.Bhd.	Malaysia	,000 MYR 32,380	SMG	100.0
Compañía Internacional de Comercio, S.A.P.I. de C.V.	Mexico	,000 MXN 122,467	SMG	100.0
Duoc Hau Giang Pharmaceutical JSC	Vietnam	,000 VND 1,307,460,710	SMG	51.0
UPSA SAS	France	,000 EUR 852,103	SMG	100.0
(2) Equity accounting method				
Yomeishu Seizo Co., Ltd.	Tokyo, Japan	,000 Yen 1,650,000	SMG	24.0

SMG=Self-Medication operations PD=Prescription Pharmaceutical operations

\*Ownership: including the portion of indirect ownership

## Shareholders Information (as of end of March 2021)

### Major Shareholders

(Thousands of Shares)

Shareholders	Number of shares	% of total
The Uehara Memorial Foundation	15,000	18.78%
Shoji Uehara	7,734	9.68%
Uehara Museum	3,900	4.88%
The Master Trust Bank of Japan, Ltd. (Trust account)	3,437	4.30%
Sumitomo Mitsui Banking Corp.	3,000	3.76%
MUFG Bank, Ltd.	3,000	3.76%
Akira Uehara	2,143	2.68%
Custody Bank of Japan, Ltd. (Trust account)	1,749	2.19%
Kajima Corporation	1,650	2.07%
Custody Bank of Japan, Ltd. (Sumitomo Mitsui Trust Bank, Limited ReTrust Account/ Sumitomo Chemical Company, Limited Employee Pension Trust Account)	1,530	1.92%

Shares less than one thousand are rounded down.

Treasury stock of 5,256 thousand shares are excluded from the above as these shares do not have voting rights.

The shareholding ratio is calculated excluding treasury stock. (Rounded to the nearest second decimal place)

### Distribution of Ownership Among Shareholders

	% of total
Financial Institutions	22.53%
Financial Instruments Firms	0.56%
Other companies	38.23%
Foreign Companies	13.30%
Individuals and Others	25.38%
Total	100.00%

The shareholder composition is calculated excluding treasury stock of 5,256 thousand shares.

(Rounded to the nearest second decimal place)

# Prescription Pharmaceutical Operations: New Drug Development - Taisho Pharmaceutical

As of May 14, 2021

In Japan

Filed

## Lusefi (Oral)

< Application	> Type2 diabetes
< Development	> In-house
< Description	> SGLT2 (Sodium-Glucose Cotransporter2) inhibitor
< Remarks	> Generic name: Luseogliflozin Hydrate Product name: Lusefi® Orally disintegrating film drug (drug form added)

## TS-152 (Injection)

< Application	> Articular rheumatism against which existing therapies have insufficient efficacy
< Development	> In-license (Licensor: Ablynx)
< Description	> Anti-TNF(Tumor Necrosis Factor)-α antibody
< Remarks	> Generic name: Ozoralizumab

Phase 3

## TS-071(Oral)

< Application	> Type2 diabetes (Pediatric)
< Development	> In-house
< Description	> SGLT2 (Sodium-Glucose Cotransporter2) inhibitor
< Remarks	> Generic name: Luseogliflozin Hydrate Product name: Lusefi®

Phase 2

## TS-142 (Oral)

< Application	> Insomnia
< Development	> In-house

# Prescription Pharmaceutical Operations: New Drug Development - Taisho Pharmaceutical

As of May 14, 2021

## Overseas

### Phase 2

#### **TS-121 (Oral)**

< Target disease > Depression

< In-house/Licensed-in > In-house

#### **TS-161 (Oral)**

< Target disease > Depression

< In-house/Licensed-in > In-house

### Phase 1

#### **TS-134 (Oral)**

< Target disease > Schizophrenia

< In-house/Licensed-in > In-house

#### **TS-142 (Oral)**

< Target disease > Insomnia

< In-house/Licensed-in > In-house

## Launch of New Products

As of May 14, 2021

### New Products Since FY2020 3Q Earnings Announcement (February 4, 2021)

Self-Medication Operations
----------------------------

#### RAIZIN SAKURA

- < Description > Limited-time offer of a flavor in the RAIZIN series of energy drink containing enXtra as a new functional material alternative to caffeine. The Sakura flavor featuring a refreshing scent at the start of spring 2021.
- < Launch > February 2021

---

#### Hitomi Care Capsule a

- < Description > A recommended daily intake of two capsules contains 9 mg of astaxanthin as functional substance. It is a food with function claims, with the functions of astaxanthin that help computer and smartphone users take care of their eyes, shoulders and back.
- < Launch > March 2021

---

#### Kaimin Care Capsule

- < Description > It is a food with function claims that contains crocetin, which reduces drowsiness and fatigue at the time of awakening by improving the quality of sleep (depth of sleep), and GABA, which alleviates a temporary feeling of fatigue caused by mentally stressful work and temporary depression.
- < Launch > March 2021

---

#### Mikan no Shizuku

- < Description > A hair regrowth treatment developed for nature-oriented women. Plant-derived active ingredients, such as dipotassium glycyrrhizinate (Glycyrrhiza), gentian extract and ginseng extract, improves the flow of blood on the skin to prevent hair losses. A natural citrus note wraps the whole hair.
- < Launch > March 2021

---

#### Tokuhon Loxy Tape

- < Description > An adhesive skin patch with efficacy against pains on shoulders and lower back. It contains three active ingredients. They are 5% loxoprofen sodium, vitamin E (tocopherol acetate) and menthol. The loxoprofen sodium blocks sources of the pain to relieve it. Vitamin E improves the flow of blood in the affected part. And the menthol adds a pleasant refreshing feel.
- < Launch > March 2021
-